TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29984430
Drug: Mystery shop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mystery shop intervention with monthly feedback to clerks and servers.
Study: 12131931
Drug: Clonazepam 2
Normalized name: clonazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam 2 mg/day for 6 weeks
Study: 9924158
Drug: Heparin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin treatment to maintain activated clotting time of >300 seconds
Study: 368535
Drug: ibuprofen 1600
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen 1600 mg daily
Study: 368535
Drug: indomethacin 100
Normalized name: indomethacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: indomethacin 100 mg daily
Study: 368535
Drug: indomethacin and
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: indomethacin and ibuprofen
Study: 27919222
Drug: Capsaicin 8%
Normalized name: CAPSAICIN 8% PATCH KIT,4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin 8% patch (30 min) plus SOC
Study: 27919222
Drug: Capsaicin 8%
Normalized name: CAPSAICIN 8% PATCH KIT,4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin 8% patch (60 min) plus SOC
Study: 21887594
Drug: Experimental diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental diet containing 600 g/kg DM of wheat middlings (WM)
Study: 21887594
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet containing 400 g/kg DM of corn
Study: 21034938
Drug: Second-look procedures
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second-look procedures (SLP) before completing chemotherapy
Study: 21034938
Drug: Second-look procedures
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second-look procedures (SLP) during treatment
Study: 21034938
Drug: No second-look
Approvals — FDA: no, EMA: no, PMDA: no
Description: No second-look procedures (SLP) during treatment
Study: 19302083
Drug: Naltrexone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (25 mg daily for 3 days prior to quit date, then 50 mg daily for 8 weeks)
Study: 16156143
Drug: Intracameral injection
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intracameral injection of 2% hydroxypropyl methylcellulose (HPMC) during trabeculectomy (group II; n = 15)
Study: 16156143
Drug: Conventional trabeculectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional trabeculectomy without HPMC injection (group I; n = 15)
Study: 8826928
Drug: Good steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Good steroid response
Study: 8826928
Drug: T-ALL treatment
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: T-ALL treatment protocols (8303, 8503-8703, and '88)
Study: 8826928
Drug: Poor in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poor in vivo steroid response
Study: 8826928
Drug: Leukocyte level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukocyte level count > 50 x 10^9/l
Study: 2124962
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V 1000 mg once daily
Study: 2124962
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V 250 mg four times daily
Study: 2124962
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V 500 mg twice daily
Study: 16516602
Drug: Quinapril at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril at a target dose of 60 mg/day
Study: 9050888
Drug: N-acetylcysteine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (oral administration)
Study: 3056288
Drug: Preoperative radiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiotherapy (34.5 Gy, divided into 15 daily doses of 2.3 Gy each)
Study: 26201299
Drug: Cabotegravir 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabotegravir 10 mg once a day
Study: 26201299
Drug: Cabotegravir 30
Normalized name: cabotegravir 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabotegravir 30 mg once a day
Study: 26201299
Drug: Cabotegravir 60
Normalized name: cabotegravir 600 MG per 3 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabotegravir 60 mg once a day
Study: 26201299
Drug: Efavirenz 600
Normalized name: efavirenz 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz 600 mg once a day with dual NRTIs
Study: 26201299
Drug: Cabotegravir (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabotegravir (all doses combined)
Study: 23592605
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg ropivacaine + 5 µg sufentanil
Study: 23592605
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg ropivacaine + 5 µg sufentanil
Study: 23592605
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ropivacaine + 5 µg sufentanil
Study: 23592605
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg ropivacaine + 5 µg sufentanil
Study: 23592605
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of ropivacaine
Study: 17709798
Drug: Tamoxifen 1
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 1 mg/day
Study: 24241787
Drug: Tamoxifen 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 5 mg/day
Study: 8916481
Drug: 3 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 weeks of exercise training (interval exercise with bicycle ergometer 15 minutes 5 times weekly, interval treadmill walking 10 minutes, and exercises 20 minutes, each 3 times weekly)
Study: 7064017
Drug: Doxorubicin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (40 mg/m2) and cyclophosphamide (700 mg/m2) administered as pulse doses once every 3 weeks.
Study: 31927549
Drug: Group TPVB
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group TPVB (20 mL of 0.25% ropivacaine)
Study: 31927549
Drug: Group LAI
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group LAI (40 mL of 0.25% ropivacaine)
Study: 30859959
Drug: Standard-of-care (SOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care (SOC) antipsychotics
Study: 23782126
Drug: 20 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg/day BH4
Study: 21719096
Drug: Abatacept (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept (10 mg/kg, maximum 1000 mg per dose) administered intravenously on days 1, 14, 28, and monthly for a total of 27 infusions over 2 years
Study: 21494892
Drug: Oxycodone HCl
Normalized name: oxycodone HCl
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone HCl IR 10 mg
Study: 17164971
Drug: 8 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 weeks of assisted exercise (daily passive extension and flexion range-of-motion exercise of the upper and lower extremities)
Study: 11843769
Drug: Heparin-coated circuit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated circuit with leukocyte-depleting arterial line filter (HF group)
Study: 22069289
Drug: vitD3 (140,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitD3 (140,000 IU monthly)
Study: 19413683
Drug: Clonidine (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.01 mg min(‐1) IV, max 0.1 mg, placebo SC)
Study: 19413683
Drug: Sumatriptan (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (6 mg SC, placebo IV)
Study: 9091692
Drug: Midodrine 10
Normalized name: midodrine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine 10 mg, 3 times per day
Study: 29253122
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy (chemotherapy)
Study: 29253122
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy (chemotherapy)
Study: 20485282
Drug: Magnesium citrate
Normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium citrate (250 ml, day before procedure) followed by 2 liters PEG (day of procedure) - group 3
Study: 1408297
Drug: Self-administered treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered treatment
Study: 12142115
Drug: Dose-adjusted warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-adjusted warfarin (international normalized ratio 2 to 3)
Study: 12142115
Drug: Aspirin 75
Normalized name: aspirin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 75 mg and clopidogrel 75 mg combination therapy
Study: 7790321
Drug: Met‐depleting TPN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Met‐depleting TPN with 5‐FU (500 mg/body per day; total 4.0 g/body) for 7 days before surgery
Study: 7790321
Drug: Conventional L‐methionine‐containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional L‐methionine‐containing TPN with 5‐FU
Study: 31684880
Drug: Azospirillum (AL)
Normalized name: AL-034
DrugBank: AL-034 (DB17471)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azospirillum (AL) with half dose of NP fertilizers (25 kg/ha N and 30 kg/ha P)
Study: 31684880
Drug: Azotobacter (AV)
Normalized name: AVS-100
DrugBank: AVS-100 (DB18068)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azotobacter (AV) with half dose of NP fertilizers
Study: 31684880
Drug: Azospirillum (AL)
Normalized name: AL-034
DrugBank: AL-034 (DB17471)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azospirillum (AL) with half dose of NP fertilizers
Study: 28173154
Drug: Extensive peritoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extensive peritoneal lavage (10 l of saline)
Study: 28173154
Drug: Standard lavage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard lavage (≤2 l of saline)
Study: 25460215
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose mCIMT (60 h)
Study: 25460215
Drug: Half dose
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half dose mCIMT (30 h)
Study: 25460215
Drug: Half dose
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half dose bimanual therapy (30 h)
Study: 25460215
Drug: Bimanual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimanual therapy (full dose)
Study: 23149871
Drug: Empagliflozin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (1 mg to 100 mg doses)
Study: 28022576
Drug: TJ-107 (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TJ-107 (2.5 g three times daily)
Study: 16393192
Drug: Professional treatment
Normalized name: ANHYDROUS DEXTROSE 5 g in 20 g / CURCUMIN 4 g in 20 g / ICOSAPENT 3 g in 20 g / CHOLECALCIFEROL 2 g in 20 g TOPICAL GEL [SOUTH MOON Propolis Professional Treatment Gel]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professional treatment for drinking problems
Study: 16393192
Drug: Broader treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broader treatment system including pretreatment assessment and additional forms of help
Study: 16393192
Drug: Self-directed change
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-directed change during and following treatment
Study: 15242012
Drug: 24 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 g/d of resistant corn starch (RS)
Study: 9066993
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg methylphenidate (MPH)
Study: 29713147
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid supplementation (Aminoglutam®) administered twice a day for 4 weeks (96 kcal, 12 g amino acids, 0.18 g fat, 11.6 g carbohydrate, and vitamins B1, B6, and C)
Study: 24990028
Drug: High intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intensity personalized physical training (32 weeks, twice a week, optional extra session once a week)
Study: 1680791
Drug: Zidovudine administered
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine administered twice daily
Study: 1680791
Drug: Zidovudine administered
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine administered four times daily
Study: 6353433
Drug: Indoramin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin (25 mg twice daily) plus hydrochlorothiazide (25 mg twice daily) or propranolol (40 mg once daily)
Study: 31601947
Drug: Anti-beta1 adrenergic
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anti-beta1 adrenergic receptor antibody concentrations < median in STEMI patients ≤60 years
Study: 31601947
Drug: Anti-beta1 adrenergic
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anti-beta1 adrenergic receptor antibody concentrations > median in STEMI patients ≤60 years
Study: 29029033
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg)
Study: 29029033
Drug: Rifaximin (1650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin (1650 mg)
Study: 16700802
Drug: Eberconazole 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eberconazole 1% cream every 12 h for 4 weeks
Study: 16700802
Drug: Miconazole 2%
Normalized name: MICONAZOLE 200MG SUPP/MICONAZOLE 2% CREAM PAK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miconazole 2% cream every 12 h for 4 weeks
Study: 3583491
Drug: Miconazole 2%
Normalized name: MICONAZOLE 200MG SUPP/MICONAZOLE 2% CREAM PAK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miconazole 2% cream
Study: 11283883
Drug: Lactulose/rhamnose solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose/rhamnose solution (1 mL/kg body weight) given at different time intervals after admission
Study: 9207820
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of misoprostol (400 micrograms)
Study: 9207820
Drug: Vaginal administration
Normalized name: Antiinflammatory products for vaginal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal administration of misoprostol (400 micrograms)
Study: 6111212
Drug: Atenolol 200
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol 200 mg daily
Study: 28627356
Drug: Aquatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquatic therapy (AT) - 30 minutes, twice weekly for 6 months
Study: 28627356
Drug: Land-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Land-based therapy (LBT)
Study: 23135868
Drug: Aliskiren 150
Normalized name: aliskiren 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 150 mg/day (increased to 300 mg/day)
Study: 11465651
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg/day
Study: 12763375
Drug: Lamivudine monotherapy
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine monotherapy after a short course of HBIg and lamivudine
Study: 10797336
Drug: Topical tetracycline
Normalized name: TETRACYCLINE HYDROCHLORIDE 30 mg in 1 mL TOPICAL SPRAY [Tetracyte Topical Tetracycline Hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tetracycline (100 ml, 2 g)
Study: 1425642
Drug: BCAA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA supplementation (5.76, 2.88 and 2.88 g per day of leucine, isoleucine and valine, respectively)
Study: 31340094
Drug: Erdafitinib (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdafitinib (8 mg per day in a continuous regimen)
Study: 17555412
Drug: Ultrasonic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic treatment
Study: 10459959
Drug: Zidovudine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (300 mg twice daily until labour, 600 mg at beginning of labour, and 300 mg twice daily for 7 days post partum)
Study: 7639221
Drug: Sucralfate suspension
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate suspension 2 g BID
Study: 2696630
Drug: Mitoxantrone containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone containing multi-drug chemotherapy
Study: 2696630
Drug: Other malignancies
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other malignancies treatment
Study: 2696630
Drug: Adriamycin or
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin or epirubicin combined with other drugs (control)
Study: 20702754
Drug: Rifampin 600
Normalized name: rifampin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 600 mg once daily for 8 days
Study: 10771458
Drug: Ketoconazole 400
Normalized name: ketoconazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 400 mg once daily for 6 days
Study: 16700666
Drug: Narrow-band UV-B
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow-band UV-B (NBUVB) plus 0.05% topical calcipotriol ointment
Study: 14715387
Drug: PCA morphine
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA morphine 1 mg/ml
Study: 14715387
Drug: PCA morphine
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA morphine 1 mg/ml plus naloxone 0.6 microg/ml
Study: 9669007
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg granisetron (Group G)
Study: 9669007
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg droperidol (Group D)
Study: 9669007
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg granisetron plus 1.25 mg droperidol (Group GD)
Study: 4061978
Drug: Albuterol (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (180 micrograms)
Study: 7636054
Drug: Cetirizine 5
Normalized name: cetirizine 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 5 mg + Albuterol
Study: 7636054
Drug: Cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10 mg + Albuterol
Study: 7636054
Drug: Cetirizine 20
Normalized name: cetirizine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 20 mg + Albuterol
Study: 28238711
Drug: Ticagrelor (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily for days 2‐90)
Study: 28238711
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg on day 1 followed by 100 mg daily for days 2‐90)
Study: 24088368
Drug: Intensive Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Insulin Therapy (IIT) protocol presumed if median Glu₁ <6.44 mmol/L
Study: 22069132
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy with medication
Study: 22069132
Drug: Medication (tricyclic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (tricyclic antidepressants or selective serotonin reuptake inhibitors)
Study: 17698578
Drug: self-administered paper-and-pencil
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: self-administered paper-and-pencil questionnaire
Study: 15328251
Drug: Valerian extract
Normalized name: valerian extract
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian extract (1000 mg nightly for 14 days)
Study: 11432623
Drug: High-dose platinum
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose platinum (cisplatin and carboplatin)
Study: 9492500
Drug: Low flow
Normalized name: high mallow flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low flow sevoflurane (0.5 l.min‐1 during pause)
Study: 9138869
Drug: Goserelin injections
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin injections (3 doses of 3.6 mg subcutaneously at 4-week intervals) followed by hysteroscopic resection if fibroids remained submucous.
Study: 30019265
Drug: Adapted physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted physical activity (APA) programme, 4 months of weekly classes of 45 min
Study: 27965257
Drug: Intravenous secukinumab
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous secukinumab 150 mg
Study: 27965257
Drug: Intravenous secukinumab
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous secukinumab 75 mg
Study: 19223739
Drug: Paclitaxel injection
Normalized name: paclitaxel Injection
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel injection NK
Study: 19223739
Drug: Taxol injection
Normalized name: Taxol Injectable Product
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Taxol injection
Study: 12622764
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (rabeprazole 20 mg b.d., rifabutin 300 mg once daily, levofloxacin 500 mg once daily for 7 days)
Study: 12622764
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (rabeprazole 20 mg b.d., metronidazole 400 mg t.d.s., bismuth subcitrate 120 mg q.d.s., tetracycline 500 mg q.d.s. for 7 days)
Study: 17285097
Drug: Citalopram (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20-40 mg daily)
Study: 28716428
Drug: High-intensity statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity statin treatment (40mg atorvastatin)
Study: 28716428
Drug: Low-intensity statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity statin treatment (20mg pravastatin)